Penumbra Presents STORM-PE Results At VIVA 2025; Trial Data Shows CAVT Plus Anticoagulation Improves Functional Outcomes Than Anticoagulation Alone In PE Patients

Author: Benzinga Newsdesk | November 03, 2025 03:06pm

• The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation
• Results of STORM-PE demonstrating superior efficacy of CAVT with anticoagulation versus anticoagulation alone were also published in Circulation today

ALAMEDA, Calif., Nov. 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectomy (CAVT™) with anticoagulation achieved significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism (PE). The data were presented at this week's Vascular Interventional Advances (VIVA) 2025 Conference. The primary results were also published today in American Heart Association's journal Circulation.

Posted In: PEN